Lexicon Pharmaceuticals Inc
LXRX1.150USD
+0.080+7.48%
交易中 （美東）報價延遲15分鐘
417.65M總市值
虧損本益比TTM
關於 Lexicon Pharmaceuticals Inc 公司
Lexicon Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於發現、開發和商業化用於治療人類疾病的藥品。該公司的產品線包括 INPEFA（索他格列淨）、LX9211 和 LX9851。索他格列淨是一種口服小分子化合物，正在開發用於治療心力衰竭和 I 型糖尿病以及 II 型糖尿病、慢性腎病和其他心血管風險因素。LX9211 是一種口服小分子化合物，正在開發用於治療神經性疼痛。該公司正在對 LX9211 進行糖尿病周圍神經性疼痛的 II 期臨牀試驗和對 LX9211 進行帶狀皰疹後神經痛的 II 期臨牀試驗。該公司正在對口服小分子候選藥物 LX9851 進行臨牀前開發，作爲肥胖症的治療方法和體重管理的工具。
公司簡介
公司代碼LXRX
公司名稱Lexicon Pharmaceuticals Inc
上市日期Apr 07, 2000
CEOMr. Michael Exton
員工數量103
證券類型Ordinary Share
年結日Apr 07
公司地址2445 Technology Forest Blvd
城市THE WOODLANDS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編77381
電話12818633000
網址https://www.lexpharma.com/
公司代碼LXRX
上市日期Apr 07, 2000
CEOMr. Michael Exton
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
持股股東
持股股東
佔比
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
股東類型
持股股東
佔比
Investment Advisor
68.24%
Hedge Fund
3.93%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
1.23%
Research Firm
0.50%
Family Office
0.06%
Bank and Trust
0.05%
Pension Fund
0.01%
Other
22.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
320
282.21M
77.71%
-40.09M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
2023Q1
274
154.64M
82.03%
-4.81M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Artal International S.C.A.
136.18M
37.5%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
38.92M
10.72%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
34.54M
9.51%
-17.43M
-33.53%
Mar 31, 2025
The Vanguard Group, Inc.
9.56M
2.63%
-278.32K
-2.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.21M
2.54%
-237.79K
-2.52%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
8.21M
2.26%
+654.37K
+8.66%
Mar 31, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Geode Capital Management, L.L.C.
3.69M
1.02%
+168.02K
+4.77%
Mar 31, 2025
GSA Capital Partners LLP
807.49K
0.22%
+807.49K
--
Mar 31, 2025
State Street Global Advisors (US)
2.61M
0.72%
-110.67K
-4.07%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0%
Texas Capital Texas Equity Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.68%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
Texas Capital Texas Equity Index ETF
佔比0%
Goldman Sachs Innovate Equity ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
